bioAffinity Technologies, Inc. (BIAF) — Cash Flow-to-Debt Ratio
bioAffinity Technologies, Inc. (BIAF) has a Cash Flow-to-Debt Ratio of -0.69x as of December 2025, meaning its operating cash flow of $-2.56 Million could theoretically repay -1% of its total liabilities ($3.68 Million) in one year. See BIAF net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
bioAffinity Technologies, Inc. Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for bioAffinity Technologies, Inc. across 7 annual periods. Also explore bioAffinity Technologies, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for bioAffinity Technologies, Inc. (2019–2025)
Year-by-year debt coverage analysis for bioAffinity Technologies, Inc.. For market capitalisation and broader financial context, see BIAF stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.53x | $-9.33 Million | $3.68 Million | ▼ -36.4% |
| 2024 | -1.86x | $-7.26 Million | $3.91 Million | ▼ -3.5% |
| 2023 | -1.79x | $-6.04 Million | $3.37 Million | ▲ +49.8% |
| 2022 | -3.58x | $-4.07 Million | $1.14 Million | ▼ -2908.7% |
| 2021 | -0.12x | $-2.05 Million | $17.24 Million | ▲ +18.1% |
| 2020 | -0.15x | $-2.21 Million | $15.22 Million | ▲ +72.7% |
| 2019 | -0.53x | $-2.49 Million | $4.69 Million | — |